Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 + bevacizumab vs FOLFIRI + bevacizumab in second-line metastatic colorectal cancer
ChiCTR2600116782Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trastuzumab rezetecan in colorectal cancer (CRC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective Response Rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600116782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116782.